Abstract
1. Stop injection/infusion immediately
2. Get extravasation kit
3. Put on (sterile) gloves
4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Original articles
Seyfer AE, Solimando DA: Toxic lesions of the hand associated with chemotherapy. J Hand Surg 8: 39–42, 1983.
Secondary literature
Summary of the product characteristics Bleomedac® (Germany), medac, September 2004.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 1, 2nd edition: A42–44, 1997.
Donislawski S, Gain M, Meyer-Jürshof A, et al: Bleomycin: -Behandlung von Paravasaten. In: Donislawski S, et al (eds) -ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 2: 23, 1994.
Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.
Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.
Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer -Chemotherapy Handbook. Appleton & Lange, 2nd edition: -109–118, 1994.
Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6 th edition: 1–17, 1999.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.
Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.
Barth J: Paravasate und deren Behandlung. In: Barth J (eds) -Zytostatika-Herstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.
Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.
Dorr RT, Von Hoff DD: Drug monographs: bleomycin sulfate. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 227–236, 1994.
Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.
Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. Ann Oncol 15: 858–862, 2004.
Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 321: 327–335, 2001.
Alley E, Green R, Schuchter L: Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14: 212–216, 2002.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Bleomycin. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_15
Download citation
DOI: https://doi.org/10.1007/978-3-211-88893-3_15
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-88889-6
Online ISBN: 978-3-211-88893-3
eBook Packages: MedicineMedicine (R0)